РЕМЕДИУМРЕМЕДИУМ1561-59362658-3534Joint-Stock Company Chicot159610.32687/1561-5936-2023-27-1-4-11Original ArticleВыбор критериев относительной терапевтической ценности лекарственных препаратов для системы здравоохраненияТолкушинАлександр Геннадьевич001ХабриевРамил Усманович002Евразийская академия надлежащих практик, Москва, РоссияНациональный научно-исследовательский институт общественного здоровья имени Н. А. Семашко, Москва, Россия15122023141109102025Copyright © 2023, АО "Шико"2023Системные изменения в здравоохранении и углубление понимания ценности человеческой жизни, благополучие людей, а также влияние использования лекарственных препаратов (ЛП) привели к выделению критериев относительной ценности ЛП. В статье представлены перечни и точные текстовые формулировки критериев относительной ценности ЛП. Сформулированы некоторые основные требования к критериям относительной терапевтической ценности ЛП, проведена оценка их потенциального взаимного влияния и предложены формулировки вопросов для сбора экспертного мнения о значении критериев относительной ценности ЛП.relative therapeutic value of medicinespharmacoeconomicsheath technologies assessmentcost-effectivenessотносительная терапевтическая ценность лекарственных препаратовфарамакоэкономикаоценка медицинских технологийклинико-экономический анализ1.Korablev V. N., Dementieva E. L. System of indicators for evaluating the effectiveness of medical care in healthcare. Far Eastern Medical Journal. 2014; (4): 94—98. (In Russ.)2.Aksenova E. I., Besschetnova O. V. Indicators of accessibility and quality of medical care, ensuring the satisfaction of the population with medical care in various countries of the world. Expert review. Moscow; 2021. (In Russ.)3.Saitgareeva A. A., Budardin S. S., Volkova O. A. Indicators and criteria for evaluating the effectiveness of medical organizations in federal and regional regulatory legal acts. Bulletin of Roszdravnadzor. 2015; (6): 12—23. (In Russ.)4.Kolbin A. S., Omelyanovsky V. V., Kurylev A. A. Analysis of solid and surrogate performance indicators of medicines included in the restrictive lists in 2016. Remedium. 2017; (5): 44—48. (In Russ.) doi: 10.21518/1561-5936-2017-5-44-485.Tikhomirova A. V. Criteria for evaluating the clinical efficacy of antitumor drugs. Bulletin of the Scientific Center for Expertise of Medicinal Products. Regulatory research and examination of medicines. 2019; 9(1): 34—40. (In Russ.) doi: 10.30895/1991-2919-2019-9-1-34-406.Zlaugotne B., Zihare L., Balode L. et al. Multi-criteria decision analysis methods comparison. Rigas Tehniskas Universitates Zinatniskie Raksti. 2020; 24(1): 454—471. doi: 10.2478/rtuect-2020-00287.Jakab I., Whittington M. D., Franklin E. et al. Patient and payer preferences for additional value criteria. Front. Pharmacol. 2021; 12: 690021. doi: 10.3389/fphar.2021.6900218.Fedyaeva V. K., Rebrova O. Yu., Omelyanovsky V. V. Comparison of methods for assessing the importance of criteria in conducting a multi-criteria analysis of decision-making on the financing of rare diseases. Medical technologies. Evaluation and selection. 2016; 3(25): 8—13. (In Russ.)9.Yagudina R. I., Serpik V. G., Dorofeeva M. Yu. Evaluation of drug therapy in patients with tuberous sclerosis using the methodology of multicriteria analysis of decision-making. Pharmaco-economics: theory and practice. 2016; 4(1): 139—147. (In Russ.) doi: 10.30809/phe.1.2016.2610.Fedyaeva V. K., Omelyanovsky V. V., Musina N. Z. et al. Application of the method of multicriteria decision-making analysis (MCDA) to develop a tool for assessing the level of therapeutic value (innovativeness) of original medicines. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2017; 10(2): 69—74. (In Russ.) doi: 10.17749/2070-4909.2017.10.2.069-07411.Nedogoda S. V., Salasyuk A. S., Barykina I. N. et al. Multicriteria analysis of the range of innovative drugs in oncohematology as a tool to support decision-making in the field of drug provision. Quality Clinical Practice. 2018; (2): 4—11. (In Russ.) doi: 10.24411/2588-0519-2018-1004012.Tolkushin A. G., Smirnova A. V., Ermolaeva T. N., Davydovskaya M. V. Fixed and separate combination of solifenacin and tamsulosin in urination disorders associated with benign prostatic hyperplasia: a choice based on price and value comparison. Quality Clinical Practice. 2019; (1): 12—18. (In Russ.) doi: 10.24411/2588-0519-2019-1006013.Lemeshko V. A., Musina N. Z., Omelyanovsky V. V. Determination of the therapeutic value of antitumor drugs. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2020; 13(3): 262—269. (In Russ.) doi: 10.17749/2070-4909/farmakoekonomika.2020.05614.Tolkushin A. G., Davydovskaya M. V., Pogudina N. L., Ermolaeva T. N. PNS271 testing of a questionnaire for assessment of relative weights of medicines value criteria. Value in Health. 2019; 22: S808. doi: 10.1016/j.jval.2019.09.217115.Tolkushin A. G., Yagudina R. I., Davydovskaya M. V. et al. A new tool for optimizing the budget for medicines based on the analysis of the cost and value of medicines: AV-platform. Modern organization of drug supply. 2018; (3): 25—34. (In Russ.) doi: 10.30809/solo.3.2018.316.Tolkushin A. G., Davydovskaya M. V., Yagudina R. I. The concept of determining the equilibrium price of innovative medicines based on their real value — value-based pricing. Remedium. 2017; (12): 6—14. (In Russ.) doi: 10.21518/1561-5936-2017-12-6-1417.Omelyanovsky V. V., Fedyaeva V. K., Rebrova O. Yu. Methodological recommendations for the use of multicriteria analysis in healthcare. Moscow; 2014. (In Russ.)